Agenus Inc. (AGEN)
NASDAQ: AGEN · Real-Time Price · USD
7.22
+0.20 (2.85%)
At close: Nov 11, 2026, 4:00 PM EST
7.22
0.00 (0.00%)
After-hours: Nov 11, 2026, 4:15 PM EST
Agenus Revenue
Agenus had revenue of $31.49M in the quarter ending September 30, 2026, with 4.14% growth. This brings the company's total for the last twelve months to $133.95M, up 25.38% year-over-year. In the year 2025, Agenus had annual revenue of $114.20M with 10.37% growth. That makes Agenus the 20,507th largest company in the world by revenue and 3,113th in the United States.
Revenue (ttm)
$133.95M
Revenue Growth
+25.38%
P/S Ratio
2.45
Revenue / Employee
$1,653,654
Employees
81
Market Cap
326.68M
Revenue by Geography
- United States 113.16M 99.1%
- Rest of World 1.04M 0.9%
Fiscal year ended Dec 31, 2025 See the full Agenus breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 114.20M | 10.73M | 10.37% |
| Dec 31, 2024 | 103.46M | -52.85M | -33.81% |
| Dec 31, 2023 | 156.31M | 58.29M | 59.47% |
| Dec 31, 2022 | 98.02M | -197.64M | -66.85% |
| Dec 31, 2021 | 295.67M | 207.50M | 235.34% |
| Dec 31, 2020 | 88.17M | -61.88M | -41.24% |
| Dec 31, 2019 | 150.05M | 113.26M | 307.92% |
| Dec 31, 2018 | 36.78M | -6.09M | -14.21% |
| Dec 31, 2017 | 42.88M | 20.30M | 89.95% |
| Dec 31, 2016 | 22.57M | -2.24M | -9.04% |
| Dec 31, 2015 | 24.82M | 17.84M | 255.67% |
| Dec 31, 2014 | 6.98M | 3.93M | 129.13% |
| Dec 31, 2013 | 3.05M | -12.92M | -80.92% |
| Dec 31, 2012 | 15.96M | 13.20M | 479.17% |
| Dec 31, 2011 | 2.76M | -603.84K | -17.97% |
| Dec 31, 2010 | 3.36M | 25.17K | 0.75% |
| Dec 31, 2009 | 3.33M | 683.36K | 25.78% |
| Dec 31, 2008 | 2.65M | -2.90M | -52.25% |
| Dec 31, 2007 | 5.55M | 4.86M | 702.20% |
| Dec 31, 2006 | 692.14K | 62.16K | 9.87% |
| Dec 31, 2005 | 629.98K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Century Therapeutics | 109.16M |
| Enanta Pharmaceuticals | 65.26M |
| Scribe Therapeutics | 33.30M |
| X4 Pharmaceuticals | 16.96M |
| Ocugen | 4.78M |
| Allogene Therapeutics | 4.64M |
| Vicore Pharma Holding AB | 383.48K |
AGEN News
- 2 days ago - Agenus price target raised to $16 from $14 at B. Riley - TheFly
- 5 days ago - Agenus announces new findings from Phase 1b C-800-1 trial of BOT - TheFly
- 5 days ago - Agenus Reports More Than Half of Patients with Refractory MSS Metastatic Colorectal Cancer Achieved Long-Term Survival Following BOT+BAL Treatment at SITC 2026 - Business Wire
- 6 days ago - Agenus Transcript: Fireside chat - Transcripts
- 6 days ago - Agenus reports Q3 revenue $31.5M, consensus $28.23M - TheFly
- 6 days ago - Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study - Business Wire
- 6 days ago - Agenus Earnings release: Q3 2026 - Filings
- 6 days ago - Agenus Quarterly report: Q3 2026 - Filings